These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16328316)

  • 1. Surveillance of adverse effects during a vaccination campaign against meningitis C.
    Laribière A; Miremont-Salamé G; Reyre H; Abouelfath A; Liège L; Moore N; Haramburu F
    Eur J Clin Pharmacol; 2005 Dec; 61(12):907-11. PubMed ID: 16328316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study.
    Bryan P; Seabroke S; Wong J; Donegan K; Webb E; Goldsmith C; Vipond C; Feavers I
    Lancet Child Adolesc Health; 2018 Jun; 2(6):395-403. PubMed ID: 30169281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Meningococcal serogroup C vaccine: a pharmacovigilance point of view].
    Bagheri H; Gony M; Montastruc JL
    Therapie; 2005; 60(3):287-94. PubMed ID: 16130227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010.
    Chaibou MS; Bako H; Salisou L; Yaméogo TM; Sambo M; Kim SH; Djingarey MH; Zuber PL; Perea WA; Pezzoli L
    Vaccine; 2012 Jul; 30(35):5229-34. PubMed ID: 22709955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass vaccination campaign following community outbreak of meningococcal disease.
    Krause G; Blackmore C; Wiersma S; Lesneski C; Gauch L; Hopkins RS
    Emerg Infect Dis; 2002 Dec; 8(12):1398-403. PubMed ID: 12498654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.
    Vannice KS; Keita M; Sow SO; Durbin AP; Omer SB; Moulton LH; Yaméogo TM; Zuber PL; Onwuchekwa U; Sacko M; Diomandé FV; Halsey NA
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S493-500. PubMed ID: 26553680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of previous immunisation on the incidence of meningococcal disease during an outbreak in a Sahelian area of Senegal.
    Chippaux JP; Diallo A; Marra A; Etard JF
    Vaccine; 2007 Feb; 25(10):1712-8. PubMed ID: 17240492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5-24 months old].
    Zhou H; Wang JY; Tan Y; Lü HY; Wang M; Cai QC; Zhang HZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):920-3. PubMed ID: 24378132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision.
    Cano R; Larrauri A; Mateo S; Alcalá B; Salcedo C; Vázquez JA
    Euro Surveill; 2004 Jul; 9(7):11-5. PubMed ID: 15318008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease].
    Gong J; Li CY; Dong BQ; Huang JZ; Quan Y; Lu WZ; Luo CH; Mao WC; Liao HZ; Fang JS; Cui XL; Xie GL; Wu XH; Lan RW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):552-5. PubMed ID: 19040035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso.
    Bentsi-Enchill AD; Zongo I; Khamassi S; Pless R; Thombiano R; Tiéndrebéogo S; Nelson CB; Duclos P
    Vaccine; 2007 Sep; 25 Suppl 1():A72-8. PubMed ID: 17544552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine.
    Wise RP; Iskander J; Pratt RD; Campbell S; Ball R; Pless RP; Braun MM
    JAMA; 2004 Oct; 292(14):1702-10. PubMed ID: 15479935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of adverse events following vaccination in the French armed forces, 2011-2012.
    Mayet A; Duron S; Meynard JB; Koeck JL; Deparis X; Migliani R
    Public Health; 2015 Jun; 129(6):763-8. PubMed ID: 25890634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of Controlled Temperature Chain (CTC) approach on immunization coverage achieved during the preventive vaccination campaign against meningitis A using MenAfriVac in Togo in 2014].
    Landoh DE; Kahn AL; Lacle A; Adjeoda K; Saka B; Yaya I; Nassoury DI; Kalao A; Makawa MS; Biey NJ; Bita A; Toke YT; Dörte P; Imboua L; Ronveaux O
    Pan Afr Med J; 2017; 27():38. PubMed ID: 28761614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.